Bristol-Myers Squibb(US:BMY) Benzinga·2026-03-07 20:30Core Viewpoint - Bristol Myers Squibb received U.S. approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, providing a new treatment option for patients suffering from this autoimmune disease [1][7]. Drug Mechanism - Sotyktu works by selectively targeting tyrosine kinase 2, which is involved in immune-driven inflammation [2]. Clinical Trial Results - In two global Phase 3 studies (POETYK PsA-1 and POETYK PsA-2), patients received either a daily 6-milligram tablet of Sotyktu or a placebo. By Week 16, approximately 54% of patients taking Sotyktu achieved an ACR20 response, compared to 34% and 39% of placebo patients [3][4]. - The treatment group demonstrated a statistically significant benefit, with about 25% of treated patients achieving an ACR50 response and meaningful improvements in minimal disease activity scores, indicating broader relief across joints, skin, and pain [4]. Expert Commentary - Company representatives highlighted the approval as a significant milestone, emphasizing Sotyktu's role in managing both skin and joint symptoms of psoriatic disease. Experts noted improved quality-of-life scores for patients on the treatment during trials [5]. Safety Profile - The safety profile of Sotyktu was similar to previous studies, with common side effects including respiratory infections, mouth ulcers, acne, and elevated muscle enzyme levels. Warnings include risks of infections, viral reactivation, and potential malignancies, necessitating tuberculosis screening before treatment [6]. Market Context - The FDA initially approved Sotyktu in 2022 for moderate-to-severe plaque psoriasis, and the recent approval expands its use to adults with psoriatic arthritis, a condition affecting up to 30% of individuals with psoriasis [7]. Stock Performance - Following the announcement, Bristol-Myers shares fell by 0.28% to $60.12 in after-hours trading [8].